The regulatory path is clear for Hologic to begin marketing its SecurViewDX breast imaging workstation. The FDA earlier this month cleared the dedicated workstation for display and interpretation of screening and diagnostic digital mammograms, as well as
The regulatory path is clear for Hologic to begin marketing its SecurViewDX breast imaging workstation. The FDA earlier this month cleared the dedicated workstation for display and interpretation of screening and diagnostic digital mammograms, as well as other images such as MRI, CT, PET, and ultrasound. The workstation can also support digital CAD programs. It will complement Hologic's Lorad Selenia full-field digital mammography system, but its use will not be restricted to this system. The SecurViewDX is FDA cleared as an adjunct to any FDA-approved FFDM system.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.